ClinicalTrials.gg
Status unknownNCT03285997Updated Sep 18, 2017

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

A Phase 3 interventional study of GC3110A and GCFLU Pre-filled syringe inj. in Influenza Vaccine, sponsored by Green Cross Corporation. Status unknown at 1 site in Korea, Republic of. Open to participants aged 6 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-18.

Sponsored by Green Cross Corporation · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
6 Months to 35 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Influenza, Human by GC Biopharma Corp. — 1 open to participants now, 1 under way, 1 of them phase 3. Influenza, Human · GC Biopharma Corp..

Planned enrollment
12th of 16
260 · median 407
Started
2017
with 1 other
Phase 3
9 of 16
none open now
Registered
13th of 16
by date

Among the 16 studies in Influenza, Human by GC Biopharma Corp., this one is the 12th largest by planned enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 13th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 16 studies in Influenza, Human by GC Biopharma Corp. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 6 Months to 35 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Influenza, Human by GC Biopharma Corp., or all of them as a file.
02

Study summary

If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Formed, study subjects eligible for participating this trial protocol were assigned to test group or control group with the ratio of 4:1 and receiving the test or control drug 1 time or 2 times.

Read the detailed description
  1. Part 1 If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Form, study subjects eligible for participating this trial protocol were assigned to test group and receiving the test drug 1 time or 2 times.
  2. Part 2 If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Formed, study subjects eligible for participating this trial protocol were assigned to test group or control group with the ratio of 4:1 and receiving the test or control drug 1 time or 2 times.

The investigator will evaluate the efficacy and safety of the test product while clinical trial.

Blood samples will be collected at visit 1 and visit 5 for immunogenicity evaluation. The study subject and their legal guardians will be educated to daily record AEs after vaccination on the patient diary to evaluate the safety.

At visit1, blood samples will be collected from randomized study subjects and investigational drug will be intramuscularly injected. However, those who had not been vaccinated with influenza vaccine, will re-visit and have the 2nd vaccination, 4\~5 weeks after the 1st vaccination.

After 4\~5 weeks since last vaccination, study subjects will visit and blood sample will be collected. And the serious adverse events occurred during 180 days after the final vaccination will be checked through the telephone visit.

The study subjects with 1 dose of vaccine will have 4 visits including Visit 1\~2 and Visit 5\~6. The study subjects with 2 dose of vaccine will have 6 visits including Visit 3\~4.

03

Conditions studied

  • Influenza Vaccine

Browse trials for

Keywords

  • Quadrivalent Influenza Vaccines
04

Who can participate

Ages eligible
6 Months to 35 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy infants aged 6 month to 3 years.
  2. Study subject was born at full term pregnancy(37 week)
  3. Study subject who understand the details of this clinical trial, decide voluntarily to participate the trial, and signed the Form

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of allergic reaction to eggs or chicken, the vaccine components
  2. Those who had been ad ministered the influenza vaccine 6 months prior to the study drug vaccination
  3. Those with immunologic impairment including immune deficiency disorders or family history about it.
  4. Those with a history of Guillain-Barre syndrome
  5. Those with a history of Down's syndrome or cytogenetic disorders
  6. Those who would be ineligible to participate the study as follows: serious chronic disease
  7. Hemophilia patients at risk of serious bleeding with intramuscular injection or those receiving anticoagulant therapy
  8. Those who have active infection or who have fever higher than 38.0℃ within 72 hours prior to the dosing of study drug
  9. Those who had been vaccinated with another vaccine within 28 days prior to the dosing of study drug or had a scheduled vaccination during the clinical trial period
  10. Those who had received an , immunity-modifying drug within 3 months prior to the dosing of study drug
  11. Those who had received immunoglobulin or a blood-derived product within 3 months prior to the dosing of study drug or is scheduled to receive those products during the study period
  12. Those who had taken antipyretic/analgesic/nonsteroidal antiinflammatory drugs within 4 hours prior to the dosing of study drug
  13. Study subject who had participated in other clinical trial within 28 days prior to the study vaccination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    GC3110A

    One injection: Day 0 Two injection: Day 0 and Day 28

    Biological: GC3110A

  • Active comparator
    GCFLU Pre-filled syringe inj.

    One injection: Day 0 Two injection: Day 0 and Day 28

    Biological: GCFLU Pre-filled syringe inj.

Interventions

  • BiologicalGC3110A

    A single 0.5mL dose intramuscular injection

  • BiologicalGCFLU Pre-filled syringe inj.

    A single 0.25mL dose intramuscular injection

06

What researchers measure

Primary outcomes

  1. Seroconversion rate for HI antibody after final injection

    the percentage of study subjects with a pre-vaccination (Day 0) HI titer\<1:10 and post-vaccination (Day 28) HI antibody titer≥1:40(Case1), or the percentage of study subjects with a pre-vaccination HI antibody titer≥1:10 and a minimum four-fold rise in post-vaccination HI antibody titer(Case 2)

    Time frame: Post-vaccination (Day 28 or 56)

  2. Seroprotection rate for HI antibody after final injection

    Time frame: Post-vaccination (Day 28 or 56)

Secondary outcomes

  1. GMT

    GMT(Geometric Mean Titer) of HI antibody titer before vaccination(Day 0) and after vaccination (Day 28)

    Time frame: Post-vaccination (Day 28 or 56)

  2. GMR

    GMR(Geometric Mean Ratio) of HI antibody titer before vaccination(Day 0) and after vaccination (Day 28)

    Time frame: Post-vaccination (Day 28 or 56)

07

Study locations

1 site
  • The Catholic Univ.of Korea Seoul St.Mary's Hospital
    Seoul, Korea, Republic of
    • Jin Han Kang, M.D.PhD · Contact
    • Jin Han Kang, M.D.PhD · Principal investigator
08

References and documents

Publications

  • Choi UY, Kim KH, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Song SE, Jo DS, Lee J, Ma SH, Kim KN, Kang JH. Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months. Vaccine. 2021 Apr 8;39(15):2103-2109. doi: 10.1016/j.vaccine.2021.03.005. Epub 2021 Mar 16. PubMed 33736920 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2017; primary completion for May 2018, 8 months later.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 8 months is close to that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2017
First posted
Sep 18, 2017
StartEst.
Sep 30, 2017
Primary completionEst.
May 31, 2018
CompletionEst.
Aug 31, 2018
Last update
Sep 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03285997
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Sep 30, 2017 (estimated)
Primary completion
May 31, 2018 (estimated)
Completion
Aug 31, 2018 (estimated)
Last update
Sep 18, 2017

Study contacts

Han-A Cha
Contact
hacha@greencross.com
+82-260-1936

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GC3110A

Start the discussion